Apellis Pharmaceuticals ( (APLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The stock price of Apellis Pharmaceuticals has been negatively impacted after Goldman Sachs downgraded the company to a ‘Sell’ rating. The downgrade was due to potential risks to the company’s near-term outlook and a lack of catalysts for share price growth. Additionally, Goldman Sachs has lowered its price target for Apellis from $26 to $18, driven by projections of lower peak sales for its product, Syfovre, by 2030 compared to consensus estimates.
More about Apellis Pharmaceuticals
YTD Price Performance: -32.99%
Average Trading Volume: 2,417,408
Technical Sentiment Signal: Sell
Current Market Cap: $2.87B
For further insights into APLS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.